title: Rethinking antithyroid drugs in pregnancy.
abstract: Uncontrolled hyperthyroidism in pregnancy poses a risk to both mother and foetus, and the optimal treatment strategy in this setting remains elusive. Instigation of pharmacological therapy or an alternative intervention during pregnancy requires careful consideration, and the evidence that has underpinned our choice of antithyroid drug has not been robust. Recent research developments have prompted us to question our practice, and reconsider our approach to managing this patient group.
authors.affiliation: Institute of Genetic Medicine, Newcastle University and Endocrine Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.
authors.forename: C
authors.initials: C
authors.lastname: Napier
authors.forename: S H S
authors.initials: SH
authors.lastname: Pearce
mesh_terms: D013956:Antithyroid Agents / Q000009:adverse effects*; D005260:Female; D005333:Fetus / Q000187:drug effects; D006111:Graves Disease / Q000150:complications / Q000188:drug therapy; D006801:Humans; D006980:Hyperthyroidism / Q000150:complications / Q000188:drug therapy*; D018811:Maternal Exposure; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D012306:Risk
chemical_list: D013956:Antithyroid Agents